Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Lineage Cell Therapeutics, Inc. (LCTX) had Receiveable Turnover of 14.89 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$9.50M |
|
$-18.61M |
|
$0.33M |
|
$9.16M |
|
$30.98M |
|
$-21.48M |
|
$2.90M |
|
$-18.58M |
|
$-18.57M |
|
$-18.58M |
|
$-18.58M |
|
$-18.58M |
|
$-18.57M |
|
$-21.48M |
|
$-20.91M |
|
200.19M |
|
200.19M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$51.00M |
|
$2.25M |
|
$62.22M |
|
$113.22M |
|
$13.98M |
|
$0.07M |
|
$22.23M |
|
$36.21M |
|
$77.01M |
|
$19.80M |
|
$77.01M |
|
220.42M |
|
| Cash Flow Statement Financials | |
$-23.09M |
|
$-2.31M |
|
$35.86M |
|
$35.99M |
|
$46.35M |
|
$10.36M |
|
$5.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.65 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
96.48% |
|
-226.11% |
|
-226.11% |
|
-220.14% |
|
-195.62% |
|
-195.90% |
|
$-23.66M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
|
Receiveable Turnover |
14.89 |
24.52 |
|
-24.13% |
|
-93.85% |
|
-16.41% |
|
-24.11% |
|
$0.35 |
|
$-0.12 |
|
$-0.12 |
|